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Abstract. Biologic products encounter various types of interfacial stress during
development, manufacturing, and clinical administration. When proteins come in contact
with vapor–liquid, solid–liquid, and liquid–liquid surfaces, these interfaces can significantly
impact the protein drug product quality attributes, including formation of visible particles,
subvisible particles, or soluble aggregates, or changes in target protein concentration due to
adsorption of the molecule to various interfaces. Protein aggregation at interfaces is often
accompanied by changes in conformation, as proteins modify their higher order structure in
response to interfacial stresses such as hydrophobicity, charge, and mechanical stress.
Formation of aggregates may elicit immunogenicity concerns; therefore, it is important to
minimize opportunities for aggregation by performing a systematic evaluation of interfacial
stress throughout the product development cycle and to develop appropriate mitigation
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strategies. The purpose of this white paper is to provide an understanding of protein
interfacial stability, explore methods to understand interfacial behavior of proteins, then
describe current industry approaches to address interfacial stability concerns. Specifically, we
will discuss interfacial stresses to which proteins are exposed from drug substance
manufacture through clinical administration, as well as the analytical techniques used to
evaluate the resulting impact on the stability of the protein. A high-level mechanistic
understanding of the relationship between interfacial stress and aggregation will be
introduced, as well as some novel techniques for measuring and better understanding the
interfacial behavior of proteins. Finally, some best practices in the evaluation and
minimization of interfacial stress will be recommended.
KEY WORDS: aggregation; analytical methods; biotherapeutic; interfacial stress; product development;
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INTRODUCTION
Protein therapeutics encounter various types of interfa-
cial stress during development, manufacturing, and clinical
administration. When proteins come in contact with vapor–
liquid, solid–liquid, and liquid–liquid surfaces, these interfaces
can significantly impact the protein drug product quality
attributes, including formation of visible particles, subvisible
particles, or soluble aggregates, or changes in target protein
concentration due to adsorption of the molecule to various
interfaces. Protein aggregation at interfaces is often accom-
panied by changes in conformation, as proteins modify their
higher order structure in response to interfacial stresses such
as hydrophobicity, charge, and mechanical stress. Formation
of aggregates may elicit immunogenicity concerns; therefore,
it is important to minimize opportunities for aggregation by
performing a systematic evaluation of interfacial stress
throughout the product development cycle and to develop
appropriate mitigation strategies.
Various types of interfacial stress are encountered through-
out both drug substance and drug product processing, storage,
and clinical use. The protein isolation and purification steps used
in the drug substance manufacturing process involve interaction
of the molecule with various solid/liquid interfaces, such as
columns and filters, processing equipment, container surfaces,
and ice during storage. The molecule is also exposed to air/liquid
interfaces as part of mixing and mechanical pumping operations.
During drug product manufacturing, the proteins are thawed and
often mixed with additional excipients before being filled into
vials or syringes. The thawing process exposes the protein to the
ice/liquid interface, then the mixing step exposes the protein to
the air/water interface while being sheared, before the filling
process exposes the molecule to high shear for a short period of
time. Once filled, opportunities for air/liquid interfacial stress are
the primary packaging, the container’s headspace, agitation
during transport, and stress during clinical administration.
Administration of the drug product is achieved using either IV
bags, syringes, or autoinjectors, in which the protein is exposed to
a variety of surfaces and materials, including plastics of IV bags
and infusion sets, in-line filters, silicone oil, and metals.
The aims of this white paper are to provide an
understanding of protein interfacial stability, explore methods
to understand interfacial behavior of proteins, and then
describe current industry approaches to address interfacial
stability concerns. Specifically, we will discuss interfacial
stresses to which proteins are exposed from drug substance
manufacture through clinical administration, as well as the
analytical techniques used to evaluate the resulting impact on
the stability of the protein. An overview of the mechanistic
understanding of the relationship between interfacial stress
and aggregation will be introduced, as well as some novel
techniques for measuring and better understanding the
interfacial behavior of proteins. Finally, some best practices
in the evaluation and minimization of interfacial stress will be
recommended.
CORRELATION BETWEEN INTERFACIAL STRESS
AND AGGREGATION
Aggregation of therapeutic proteins can be induced by
stresses encountered at vapor–liquid, solid–liquid, and liquid–
liquid interfaces (Fig. 1) (1). Aggregation typically involves
some degree of protein conformational change, relative to the
folded monomer, that allows two or more proteins to form
interprotein bonds that possess similar or greater stability
than the intraprotein bonds of the native folded structure.
The corresponding growth of aggregates typically occurs
through addition of monomers and/or through combining
aggregates to form soluble high molecular weight (HMW)
aggregates. The mechanism by which the stresses encoun-
tered at interfaces promote protein aggregation relative to
that in the bulk of solution is less well established. Whether
the proteins distort/unfold and self-assemble into aggregates
at the interface, and/or whether they release from the
interface and further aggregate while in the bulk solution
(or even disassemble and refold) is not definitively settled. In
principle, each type of interfacial species can reversibly
exchange with the corresponding bulk species through
convective and/or diffusive mass transport between the bulk
and interfaces. The adsorption and desorption processes may
be at equilibrium or under mass-transfer control. If under
equilibrium control, gentle sample mixing processes are not
expected to affect the concentration of adsorbed species;
however, if under mass transfer control, then mixing should
enhance the adsorption and/or desorption rates via convec-
tive mass transfer.
While long-term exposure to interfaces can be detrimen-
tal to the physical stability of therapeutic proteins, transient
exposure to interfaces in combination with mechanical
disruption of the interface (e.g., agitation, mixing, pumping)
is particularly conducive to causing protein aggregation.
Interfacial exposure and shear stress typically occur together,
but it is unlikely that the shear stress alone causes protein
aggregation (2). Numerous reports in the literature support
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the hypothesis that protein adsorption to interfaces, followed
by subsequent denaturation and aggregation at the interface,
leads to formation of protein particulates and soluble
aggregates. In particular, due to the dilution of surfactants
typically included in formulations to stabilize proteins against
interfacial stress, handling and transportation of protein drugs
prepared in IV infusion bags can result in substantial
aggregation due to the air–liquid interface present in the
bags. By removing the air headspace, and thus eliminating the
air–liquid interface in the IV bag, the bags can undergo
agitation with essentially no protein aggregation (3,4). One
marketed biologic, LUMIZYME® (Genzyme Corporation,
Cambridge, MA), explicitly instructs for the removal of air
from the IV bag Bto minimize particle formation because of
the sensitivity of LUMIZYME® to air–liquid interfaces^ (5).
Similar to IV bag agitation, agitation of a mAb in a drug
product vial with air headspace led to extensive aggregation,
whereas shaking under identical conditions without the air
headspace substantially limited the observed aggregation (6).
Other investigators have studied the effect of agitation in
siliconized versus unsiliconized prefilled syringes and found
that the presence of silicone oil exacerbated the agitation-
induced aggregation of a variety of protein therapeutics (7–9).
Because protein adsorption to interfaces is frequently limited
to the formation of a monolayer (10), rather than multilayers,
increases in protein concentration in the bulk solution can
result in an inverse relationship between the percent of
protein aggregated versus the bulk concentration (11).
Typically, interfaces lead to extensive protein aggrega-
tion in combination with a mechanical stress, which deforms,
eliminates, or physically perturbs the interfacial protein film.
The IV bag agitation study referenced above demonstrated
that static storage in the IV bag, even with the air headspace
present, did not result in aggregation (3). The formation of
protein aggregates during agitation of siliconized prefilled
syringes stopped once the agitation halted (7). Similarly for a
mAb, halting agitation of a drug product vial also stopped
aggregation (12). A fundamental study of mAb aggregation
at air–liquid interfaces determined that interfacial shear stress
caused substantially more protein particulate formation
compared to bulk shear stress. This study also indicated that
dilatational compression of antibody films that have been
exposed to air for longer, and are therefore more denatured,
resulted in shedding of protein particulates into the bulk
solution (13). Similarly, repeated lateral compression and
expansion of mAb adsorbed to an air–liquid interface
resulted in comparable protein aggregation compared to an
agitation study (14). While these previous two studies
demonstrated compression of interfacial protein films causes
protein particulates, other studies showed a similar result for
protein films at air–liquid (15) and oil–liquid (16) interfaces
only when the films were repeatedly perturbed with a needle
during vial rotation. The literature reports referenced here,
along with many others, demonstrate that protein therapeu-
tics can aggregate when exposed to interfaces, particularly in
combination with mechanical stresses that deform or perturb
the interfacial protein layer.
INTERFACIAL STRESS IN DRUG SUBSTANCE
DEVELOPMENT
Biologics are developed and manufactured in two major
stages. Biologic drug substance is the purified bulk material
that has been concentrated to the target protein concentra-
tion, partially (or fully) formulated, and typically frozen until
initiation of drug product manufacturing. The drug product is
the fully formulated protein solution contained in a vial,
syringe, or other delivery device that is ready for patient
administration. Both protein drug substance and drug product
process development and manufacturing workflows can
expose proteins to various interfacial stress conditions
(Fig. 2). During drug substance manufacturing, the protein
is taken through a series of unit operations, including harvest,
centrifugation or filtration for removal of cell debris, purifi-
cation via column chromatography, filtration, virus reduction,
concentration, and formulation/storage. In particular, the
drug substance filtration, freezing/thawing, as well as unit
operations that combine mechanical and interfacial stresses
are particularly impactful and will be detailed here.
Aqueous Phase
bulk
protein
adsorbed
surfactant
adsorbed
protein
adsorbed network 
of proteins
Fig. 1. Protein interfacial behavior. Proteins from the bulk solution can adsorb to the interface leading to an adsorbed network of proteins.
Surfactants can mitigate this adsorption. Modified from Morris et al. (1)
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Filtration
Several steps in the drug substance manufacturing
process can lead to interfacial stress due to interaction with
various types of filters. First, following protein expression in
the production bioreactor, a filtration operation is employed
to remove cells and/or solid cellular debris. The industry
standard for large-scale manufacturing involves a disk-stack
centrifugation step, followed by normal flow depth filtration.
Further purification is typically achieved through one or more
chromatography operations to isolate the protein of interest,
while removing impurities and increasing concentration.
Purification of most mammalian cell–derived biologics in-
cludes a virus removal step, which is typically a normal flow
operation. Additionally, multiple normal flow filters are
placed throughout drug substance processing; in particular,
particle reduction or microbial control filters are commonly
placed before the load and pools of each process step (17–20).
During drug substance manufacturing, protein solutions
are often concentrated and/or buffer exchanged using an
ultrafiltration/diafiltration (UF/DF) process, which is a
membrane-based tangential flow filtration (TFF) process
where products are exposed to multiple pump passes,
recirculation, and mixing. Likewise, in aseptic drug product
manufacturing, compounded protein bulk solutions are fil-
tered for bioburden reduction or sterile filtration using
normal flow filtration. While both operations are
membrane-based filtration unit operations, the differences
are mainly the direction of the fluid flow relative to the
membrane and the total time spent in contact with the
membrane, which thus affects the total amount of shear and
surface exposure the molecule is exposed to throughout the
filtration process.
During each of these filtration processes, high levels of
shear stress are often generated at the interface of the filter
membrane and the protein solution. Interfacial stress may
promote protein–protein interactions, or even lead to protein
conformational rearrangement to reduce the energy of
interaction, which could further lead to protein aggregation
or particle formation (21–23). In the ultrafiltration process,
the protein concentration at the membrane interface may be
much higher than the overall bulk solution. This might further
result in membrane fouling and boundary layer polarization
near the filter membrane. All these factors could potentially
lead to protein aggregation (24–26). The filtration force is
closely related to the membrane pore size and the distribu-
tion. It has been reported that filtration forces through
polyvinylidene fluoride (PVDF) filters are lower than those
through polyethersulfone (PES) filters (27). Although both
sterile filters have a nominal size of 0.2 μm, scanning electron
microscopy (SEM) images collected as part of the study by
Allmendinger et al. showed that the PVDF filter investigated
had larger pore sizes as compared to the PES filter tested.
Mercury porosimetry also confirmed that the PVDF filter had
a wider pore size and relatively more heterogeneous pore size
distribution (27).
In addition to pore size and distribution, the interfacial
stress during filtration is also impacted by the surface
properties of the filter membrane and the physical properties
of the filtrates. It has been reported that the interfacial
adsorption–desorption of the protein to and from hydropho-
bic interfaces during ultrafiltration/diafiltration is the principal
cause of particle formation, and the level of surfactant-free
particle formation depends on the colloidal stability of the
protein (28). Though formed particles can likely be removed
through further downstream filtration processes, the exposure
of the molecule to this interfacial stress may still potentially
have an impact on the filterability of the protein solution.
These systems may require alternate strategies, such as
performing UF/DF at low conductivity, adding additional
stabilizer(s) to improve colloidal stability, or adding surfac-
tants, such as polysorbate, to the process stream (28).
Frequently, polysorbate is found to be a critical excipient
that helps to protect the protein solution from interfacial
stress during various unit operations (29). However, if
included in the UF/DF operation, polysorbates can be
retained with the protein. Thus, in many cases, surfactant is
not added until after the UF/DF unit operation, so this
protectant is not present until the end of drug substance
manufacturing. Additionally, because polysorbate adsorption
to the membrane is often encountered during the filtration
process, any polysorbate adsorption during filtration needs to
be carefully evaluated. If significant adsorption is observed,
mitigation strategies need to be in place in order to both
monitor and control the adsorption, to ensure that the
surfactant concentration postfiltration meets the intended
requirements. During filtration process development for both
drug substance and drug product, laboratory-scale studies are
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Fig. 2. Process flow diagram that indicates types of interfacial stress that can occur during unit operations for drug substance and drug product
manufacture, as well as upon transportation and storage
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recommended in order to screen suitable filter membranes
and choose the right filter with appropriate size. In particular,
in certain cases, an appropriate product flush volume may be
warranted during drug product manufacture to ensure filter
adsorption does not lead to vials with reduced levels of
protein or excipients. The predetermined filter flush volume
can be assessed based on the filter adsorption behavior in
laboratory-scale studies, then further confirmed or adjusted in
at-scale studies based on the sterile filtration and filling
process during drug product manufacturing.
Mechanical Shear Stress/Mixing
Mechanical shear stresses may be introduced from a
variety of the manufacturing equipment utilized throughout
drug substance and drug product manufacturing, including
gas sparging, centrifuges, pumps, agitators, and flow-through
plumbing. Generally, highly polished, slower moving mechan-
ical parts are designed into the process equipment, and where
required, pumps with lower RPM and low shear impellers are
employed. Plumbing and piping are typically sized to ensure
linear velocities remain low enough to avoid highly turbulent
flow regimes, typically targeting < 5 ft/s (19). To assess the
susceptibility of a biologic to mechanical shear degradation,
lab-scale risk assessment tools such as flow-through capillaries
or rotating disks have been employed (30,31).
Across the drug substance manufacturing process, air/
liquid interfaces must be considered and minimized to
prevent negative impacts to the protein of interest. Due to
sparging in bioreactors, shear protectants are employed to
prevent damage to the cells (32,33), while antifoam agents are
employed to prevent foaming (34). Plumbing and pumps are
designed to operate fully flooded to prevent unnecessary
exposure to air/liquid interfaces. Process-intermediate mixing
should be controlled to maintain gentle agitation and avoid
the formation of a vortex, while ensuring agitators remain
fully submerged. Stainless steel tanks are commonly used for
process pool collection or TFF retentate recirculation, where
solution flows through a dip tube into the tank. The design
and location of these dip tubes are important to minimize and
avoid violent air/liquid interfaces and prevent foaming. To
assess the susceptibility of a biologic to air/liquid interfaces, a
variety of methods have been employed, including shaking in
a partially filled vial, mixing with deep vortex, and mixing
with partially submerged agitator.
Several mixing unit operations take place during both
drug substance and drug product manufacturing processes,
such as diluent mixing and concentrate preparation; adjusting
the solution pH, concentration, and/or conductivity to the
appropriate conditions for the subsequent process step; etc.
These mixing operations are often performed in mechanically
agitated tanks. During the agitation step, inappropriate
mixing conditions may lead to extensive foaming and/or
cavitation for protein solutions. The air/liquid interface is
hydrophobic, resulting in the adsorption of surface-active
molecules like proteins to this surface. The interfacial
exposure may lead to at least partial unfolding of the protein,
hence exposing their hydrophobic core and promoting
protein–protein interactions and aggregation. Stirring forces
these partially unfolded species into the bulk and allows more
protein to be exposed to the interface. For instance,
recombinant human growth hormone solutions (0.5 mg/mL)
mixed by vortexing for just 1 min have been shown to lead to
as much as 67% of the protein precipitating as noncovalent
insoluble aggregates (35).
A recent review paper from Thomas et al. focuses on the
effects of shear stress on proteins in solution (2). This work
suggests that protein aggregation or instability is not solely
induced by mechanical shear, and other factors such as
interfacial effects are often found to be the primary mecha-
nisms, or at least significant contributing factors. Kiese et al.
evaluated the impact of agitation on proteins by using
different agitation methods and found that shaking and
stirring resulted in the formation of different numbers of
particles (36).
Appropriate mixing parameters are critical to ensure a
homogeneous product while minimizing shear-induced prod-
uct degradation throughout the manufacturing process. Char-
acterization of mixing processes, determination of the overall
level of mixing, and understanding the behavior of the
protein in the mixing tank are all critical for manufacturing,
especially during the compounding process. In particular,
bottom-mounted mixers can impart significant shear stress on
the bulk drug product during mixing operations (37).
Generally, stirred mixing tanks can be evaluated through
experimental investigation of the impeller design, tank
geometries, and fluid rheology; however, due to material
limitations during the earlier development stages of drug
product manufacturing, the at-scale experimental approach
could be challenging. Instead, platform knowledge of the
mixing unit operation can be leveraged, or scaled-down
experiments can be performed. The pH, osmolality, and/or
protein concentration can be measured through sampling
from the bottom, middle, and top of the mixing tank.
Additionally, protein solutions should be exposed to various
interfacial and shear stresses, with subsequent analysis of
specific critical and product quality attributes (for example,
size variants such as formation of particulates, subvisible
particles, and soluble aggregates; chemical modification of the
monomer; etc.) (38). Establishment of laboratory scale down
models to qualify the design space for the process parameters
of these key unit operations by simulating the normal
operation ranges (NOR) as well as proven acceptable ranges
(PAR) for unit operations is recommended. As an alternative
to scale down models, an at-scale worst-case mixing study
could be performed as part of engineering runs or perfor-
mance qualification runs.
Impact of Freeze–Thaw on Protein Stability
Biologic drug substances are typically frozen for long-
term storage, and then thawed at the start of drug product
manufacture. Drug product containers can also experience
unintentional frozen excursions during shipping and/or stor-
age. While a frozen drug substance allows time to elapse
before drug product manufacture without affecting overall
stability, and permits the manufacture of multiple drug
products from a single drug substance lot, multiple freeze/
thaw cycles can have a negative impact on product quality.
Multiple stresses are associated with freeze–thaw, including
freeze concentration, pH changes, mechanical stresses, and
low temperature per se which could result in cold
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denaturation. In addition, freezing (water-to-ice transforma-
tion) creates extensive ice/solution interfaces, and it has been
suggested that freeze-induced destabilization of proteins is
related to exposure of the protein molecules to these
interfaces (39). As formulated proteins freeze, the formation
of ice crystals excludes the solutes and protein, causing
cryoconcentration. In formulations that contain a crystalliz-
able solute, such as NaCl, mannitol, PEG, sorbitol, or
trehalose, freezing can result in secondary solute+water
crystallization (40–43). The freeze-concentrated solutions
(FCS) can then be exposed to either these crystals at the
resulting solute/FCS interface, or to ice/FCS interfaces.
A second type of freezing-created interface that can lead to
protein destabilization is caused by the formation of air bubbles
during freezing. As a material is frozen, growth of ice crystals
results in increase in the concentration of all solutes present in
the sample, including dissolved air gasses (predominantly
nitrogen and oxygen). As these gasses become more concen-
trated, air bubbles form, creating additional pathways for
surface-related protein instability due to newly formed
solution/air interface (44). The appearance of air bubbles during
freezing has been directly observed by optical microscopy (45)
and indirectly by small-angle neutron scattering (SANS) (46).
Protein adsorption onto these freezing-formed air bubbles and
protein destabilization due to the additional air/solution inter-
face can therefore be expected, although the relative signifi-
cance of this potential destabilization mechanism has not been
studied. Finally, additional interfaces could also be created in the
maximally freeze-concentrated solution when it is cooled below
the glass transition temperature, as suggested in a recent study
of a model sorbitol–water system (47). A sorbitol–water mixture
with a composition representative of the maximally freeze-
concentrated solution was studied by the SANS method. It was
reported that cooling of the sample below its calorimetric Tg
(glass transition; approx. 210 K) resulted in the development of
domains with well-defined and sharp interfaces on the
submicrometer length scale, probably as a result of the
appearance and growth of microscopic voids in the glassy
matrix. Importantly, these interfaces persisted even when the
sample was heated back to above its Tg; therefore, these
interfaces could represent an additional source of protein
surface-related instability during freeze–thaw and freeze–dry-
ing/reconstitution.
Several key studies have demonstrated clear correlations
between freezing (i.e., ice formation) and protein instability.
Conformational changes of globular proteins were studied by
employing the phosphorescence emission of tryptophan (Trp)
residues as a monitor of the conformational changes of six
proteins in response to variations in conditions of the medium
(48). Changes in well-structured compact cores of the
macromolecules were monitored by the direct correlation
between the phosphorescence lifetime τ and the rigidity of
the protein matrix surrounding the chromophoric probe. The
solidification of water markedly decreased τ and indicated
unfolding-related changes in conformation of the proteins,
which was related primarily to the protein–ice interaction.
Additionally, Trp florescence was employed to monitor
unfolding of an azurin mutant C112S from Pseudomonas
aeruginosa. The results obtained with C112S azurin indicated
that the stability of the native fold may be significantly
perturbed in the frozen solutions depending mainly on the
size of the liquid solution pool in equilibrium with the solid
phase (49).
In more recent studies, evidence of partially unfolded
proteins at ice interfaces has been observed by infrared
microscopy (39,50,51). We should note that, while these
studies provided convincing evidence that destabilization of
protein could be induced by formation of ice, it is not obvious
if such destabilization is the result of the direct protein/ice
interaction, as other mechanisms can be invoked. For
example, it was suggested that the observations of freeze-
induced protein destabilization do not necessarily prove that
there is a direct ice/protein interaction (i.e., sorption of
protein molecules on ice crystals), as the same results could
be explained by a partitioning of protein into quasi-liquid
layer (52). The quasi-liquid layer (also known as liquid-like
layer) is a thin film of liquid water on the surface of ice
crystals, which exists well below the ice melting temperature
even in pure water (53). Estimations of the thickness of the
layer vary widely, from a few angstroms to up to a
micrometer (54). Protein molecules in the quasi-liquid layer
could be exposed to destabilizing stresses, such as an
increased local acidity due to the negative charge on the
surface of ice crystals (55). The ice surface was shown to carry
negative charge when in equilibrium with solution at pH
values higher than 4; the negative charge is balanced by the
elevation in the local concentration of cations, including
protons, in the quasi-liquid layer next to the ice surface, with
the corresponding increase in the local acidity.
Understanding the mechanism for freeze-induced protein
stabilization is essential to the development of appropriate
stabilization strategies. For example, if a main destabilization
pathway were direct sorption of protein molecules onto ice,
minimization of surface area of ice crystals would be a sensible
approach. On the other hand, if protein is partitioned in the
quasi-liquid layer or resides predominantly in the bulk freeze-
concentrate, stabilization would involve modification of the
amorphous protein environment, where the following ap-
proaches could be considered:
& Minimize partitioning of the protein into the
layer (e.g., more time for protein to diffuse out of the
layer to the bulk)
& Reduce acidity gradients between the surface of
ice crystals, quasi-liquid layer, and the bulk (e.g.,
increase salt concentration)
& Reduce pressure built-up (e.g., slower growth of
ice crystals)
& Avoid phase separation by use of a cryoprotector
To conclude, evaluation of freeze–thaw stability is a
necessary part of any protein formulation development process
(56). It was also pointed out that freeze–thaw cycling experi-
ments, which are usually performed with smaller samples sizes,
are not necessary predictive of long-term frozen stability of
proteins in larger amounts (57). Stability differences between
small- and large-scale samples of the same formulation could be
related to different ice nucleation and crystal growth patterns
and, therefore, variations in interfaces proteins are exposed to
on different scales. Accordingly, a surfactant such as polysor-
bate, which competes with proteins for interfaces, can improve
the stability of frozen proteins, as demonstrated, e.g., by
Schwegman et al. (50).
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INTERFACIAL STRESS IN DRUG PRODUCT
DEVELOPMENT
During drug product manufacturing, a drug substance
may be mixed with additional excipients, often after thawing,
before being filled into vials, syringes, and other devices. The
thawing process exposes the protein to the ice/liquid inter-
face, then the mixing step exposes the protein to the air/water
interface while being sheared via stirring. The effects of these
stresses on biologics were described above. However, the unit
operation that likely results in the most interfacial stress is the
filling process. Once filled into vials, opportunities for
exposure to interfacial stress emerge during storage, trans-
port, and clinical administration.
Drug Product Filling
The drug product filling process can affect product
quality attributes, since the protein solution may be exposed
to shear, friction, and cavitation during this unit operation.
Several factors, including the filling pump mechanism, contact
material, filling speed, and filling needle size, can all affect the
overall stress encountered by a protein during the filling
operation. For instance, Noyak et al. reported that the rotary
piston pump generated more protein subvisible particles
compared to the rolling diaphragm pump, peristaltic pump,
and time-pressure pump (58). Any foreign particles generated
during filling will not only affect protein stability but also pose
a significant risk of causing immunogenicity (59,60). The
authors attributed possible factors to be the narrow annular
gap that produced high shear and friction, as well as the
maximum exposure of the product to metallic/ceramic
surfaces during filling. Biddlecombe et al. (61) have also
reported significant levels of protein aggregation and precip-
itation in therapeutic antibodies due to shear in the presence
of a solid–liquid interface. Therefore, filling systems and
processes should be well understood and carefully selected
for each drug product, especially for any protein molecules
that are known to be highly sensitive to shear stress.
Though the filling system is often a fixed parameter due
to the equipment setup in the filling line in a given
manufacturing facility, a well-designed, product-specific pump
filling study and/or recirculation laboratory study is recom-
mended to evaluate the molecule susceptibility to filling stress
and to identify any potential risk associated with the filling
process. This type of study can be used to optimize filling
parameters and confirm that the product quality attributes are
not compromised during a worst-case filling process. The key
for the suggested laboratory study is to use a representative
filling pump (filling mechanism, contact material) with
representative filling parameters such as nozzle size (time-
over-pressure filling technology), filling speed, filling needle
size, etc. During the technology transfer to a clinical or
commercial manufacturing facility, an engineering run is
typically performed to confirm the process feasibility.
Storage of Protein Drug Products
Achieving desirable storage stability is one of the major
challenges in the development of protein drugs. Proteins can
experience a variety of environmental stresses during storage
and degrade via different pathways. Interfacial stress is one of
the primary causes of protein instability during storage.
Protein drug products can be stored in various container–
closure systems, such as vials, prefilled syringes, and stainless
steel containers, and during IV infusion, in disposable plastic
bags. Depending on the container–closure systems used,
proteins can be exposed to various types of interfaces during
storage, such as air–liquid interface, solid–liquid interface,
and oil–water interface. Understanding the mechanisms of
interface-induced protein instability is of great significance to
the development of stable protein formulations and selection
of appropriate storage conditions.
Exposure of Drug Products to the Air–Liquid Interface
During Storage
Aqueous solutions of therapeutic proteins are exposed to
the air–liquid interface due to the vial headspace or when
bubbles are present. Proteins can adsorb to the air–liquid
interface and form a viscoelastic interfacial film (13), with the
same mechanism as that described during stirring above.
Agitation during shipping can enhance air–liquid interface–
induced protein aggregation by increasing the area of air–liquid
interface and by accelerating the transport of denatured proteins
from the air–liquid interface back to the bulk solution. Liu et al.
showed that compression of the air–liquid interface promotes
aggregation at the interface and consequent release of
aggregates/particles into the bulk solution (62).
Agitation studies are routinely carried out during formu-
lation and process development to assess the air–liquid
interfacial stability of therapeutic proteins. The variables
tested in agitation studies usually include method of agitation
(such as stirring and shaking), intensity of agitation, size of
headspace (in vials) or bubble (in prefilled syringe), and
container orientation. Adsorptive loss of protein, structural
and conformational change, aggregation, and particle forma-
tion are usually the key parameters to monitor in an agitation
stability study. A number of techniques can be used to
monitor the adsorption of proteins to the air–liquid interface
and the strength of protein–protein interaction at the
interface, including confocal microscopy, interfacial
ellipsometry and X-ray/neutron reflectivity, and dilatational
interfacial rheology (63). Other techniques, such as Fourier
transform infrared spectroscopy (FTIR) and nonlinear vibra-
tional spectroscopy, can be used to probe the structure and
conformation of proteins at the interfaces (63). Surfactants,
such as polysorbates, can prevent the adsorption of proteins
to the air–liquid interface and are very effective at mitigating
air–liquid interface–induced protein instability. Formulation
conditions that can help improve protein colloidal stability
may also enhance air–liquid interfacial stability of proteins.
Exposure of Drug Products to the Solid–Liquid Interface
During Storage
The solid–liquid interface of container–closure systems is
another type of interface that proteins encounter during
storage. It has been shown that proteins can adsorb to various
types of solid surfaces, including glass, plastic, rubber, and
metal. Adsorptive loss of proteins can significantly reduce the
dose that can reach patients and is of a particular concern to
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therapeutic protein products stored at a low concentration. A
clinically well-studied example in this regard is insulin. It has
been demonstrated that insulin can adsorb to various types of
containers such as glass vials, plastic vials, and infusion
bottles, which can result in 20–60% reduction in the dose
available to patients (64–66). Adsorption to solid surfaces
may also promote protein unfolding and aggregation. Dena-
tured proteins, once desorbed from solid surfaces, can form
potential nucleation sites and trigger protein aggregation in
the bulk solution. Particles shed from solid surfaces encoun-
tered during manufacturing and storage, such as glass and
stainless steel, can also act as potential nuclei and induce
protein aggregation in bulk solutions (67,68).
In addition to physical degradation, contact with solid
surfaces can induce chemical degradation and protein cleav-
age. Redox-active metals, such as iron and copper, can
catalyze the oxidation of proteins stored in stainless-steel
vessels (69,70). Smith et al. showed that copper can catalyze
the cleavage of antibody in the hinge region (71). During
formulation development, an important part of the container
compatibility evaluation is the solution depletion study, which
is used to evaluate the adsorption of proteins to container
surfaces. In this study, liquid-state proteins are incubated in
the containers of interest for various amounts of time. The
protein concentration is measured before and after the
incubation to obtain the adsorption–time curve. Surface
adsorption of proteins can often be mitigated by adjusting
the pH and ionic strength or by the addition of suitable
excipients, such as surfactants, depending on whether adsorp-
tion is predominantly driven by electrostatic or hydrophobic
interactions. However, formulation strategies used to mitigate
against an electrostatically driven interaction (i.e., storage in a
glass container) may not be effective in a situation where
hydrophobicity is driving the interaction between the protein
and the container. Alternatively, a container material/coating
that has a low adsorption profile to the protein of interest
should be selected.
Exposure of Drug Products to the Oil–Liquid Interface During
Storage
A third type of interface that proteins can be exposed to
during storage is the oil–water interface. Silicone oil is
commonly used as lubricant or coating in prefilled syringes
and other pharmaceutical containers. Protein aggregation
induced by silicone oil can be a challenge in the development
and commercialization of therapeutic protein products (72),
though the use of surfactant can mitigate this aggregation.
Proteins can adsorb to the hydrophobic silicone oil–water
interface and form a monolayer, which may result in the
perturbation of protein structure and conformation (8).
Agitation can significantly enhance silicone-oil–induced pro-
tein aggregation, presumably via increasing the area of
silicone oil–water interface and accelerating the transport of
structurally perturbed proteins from the oil–water interface to
bulk solution. Carpenter et al. showed that there is a
synergistic effect between silicone oil and agitation in the
stimulation of the aggregation of monoclonal antibodies. The
stability of monoclonal antibodies in the presence of silicone
oil is better correlated with their colloidal stability, rather
than their conformational stability (73). Randolph et al.
demonstrated that ionic strength can affect the structure and
aggregation propensity of antibodies adsorbed to silicone-oil-
water interfaces (74). The sensitivity of therapeutic proteins
to silicone oils can be studied by a silicone oil spiking study
during formulation development. Considering the synergistic
effect between agitation and silicone oil in the stimulation of
protein aggregation, agitation stress is often applied as part of
silicone oil spiking studies to simulate actual storage or
transportation conditions. As with the solid/liquid interface,
the use of surfactant and optimization of solution pH and
ionic strength are important strategies for mitigating silicone-
induced adsorption and aggregation, and most commercial
formulations for biologics that will be delivered in prefilled
syringes contain a surfactant. In the studies cited above by
Randolph and Carpenter, surfactant was shown to ameliorate
protein–silicone oil adsorption and subsequent protein aggre-
gation. During the development of therapeutic proteins that
are highly prone to silicone oil–induced aggregation, silicone
oil-free syringes or syringes with other coatings such as
Teflon™ can be considered. Additionally, compared with
standard silicone coating, a novel cross-linked silicone coating
is shown to be able to reduce protein aggregation and particle
formation (75).
IN-USE STABILITY STUDY OF INJECTABLE
BIOLOGICAL DRUG PRODUCTS
The integrity of biological drugs for administration in
clinical settings is very important because it affects not only
the efficacy of the drugs but also the safety of patients.
Understanding postproduction handling risks is therefore
critical to the development of a robust product (76). The
purpose of in-use stability testing is to establish a period of
time for the preparation and administration of biological
drugs used in the clinical settings while retaining quality
within accepted specification. At this time, biological drugs
are delivered via intravenous injection of either neat drug
product or product that has been diluted with vehicle to
achieve specific dosages in a clinical setting, or subcutane-
ously by various devices that are often self-administered by
the patient. For IV administration, the commercially available
fluids 0.9% sodium chloride injection, USP (normal saline),
or 5% dextrose in water (D5W) are widely used as diluents.
The infusion solutions for administration encounter various
materials throughout the preparation and administration
period, including syringes, tubes, IV bags, and in-line filters.
In certain cases, it has been reported that the IV bag
materials have an impact on aggregate formation (4).
Additionally, the diluted solution may contain particles due
to the lower concentration of surfactant after dilution (77);
however, infusion solutions containing certain levels of
protein aggregates or particles are not suitable for IV
administration because they may reduce potency or increase
immunogenicity (78). In-line filters are therefore often used
to prevent any formed particulate matter from reaching the
patient; however, protein adsorption to this filter or to other
surfaces encountered throughout administration can lead to
the patient receiving less than the intended dose, especially
for very low dose therapies. Thus, in-use stability should be
evaluated as a part of formulation development to avoid
unforeseen problems.
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Due to the high variability in clinical study designs, no
specific guidance is available on defining the scope of in-use
stability studies. Knowledge of how a product is intended for
use in clinical settings is necessary prior to conducting the in-
use stability study. However, in-use stability studies typically
evaluate the compatibility of drug products with the diluents
normal saline or D5W, along with various syringes, closed
system transfer devices, tubes, IV bags, transfer lines, and in-
line filters. Various concentrations of diluted drug products
and flow rates should also be qualified. After preparation of
the dosing solution, initial samples should be collected, then
the infusion solutions should be exposed to the appropriate
room temperature/room light conditions representative of the
clinical environment before infusion. Both initial and infused
samples should be tested, and intermediate samples can be
tested, as needed. Generally, the samples should be aged
longer than expected clinical use time in order to ensure the
stability of the product throughout the longest allowable
preparation, storage, and administration period. Microbial
testing is not required when the infusion samples are stored at
room temperature up to a maximum of 4 h because the
assumption is made that the infusion solutions prepared
aseptically and contained in sterile bags will remain sterile
for this period of time. The analytical tests performed on the
samples usually include those to probe levels of soluble
aggregates, particles, charge variants, and fragmentation, as
well as protein concentration, appearance, and pH. In
particular, the HIAC liquid particle counter is the instrument
often used for subvisible particle detection following guidance
of USP <787> Subvisible Particulate Matter in Therapeutic
Protein Injection, using small volumes and designed specifi-
cally for biologics, or USP <788> Particulate Matter in
Injections. As stated in USP <788>, pass/fail limits for HIAC
particle counts for small volume parenteral products (less
than 100 mL) are 6000 per container for particles larger than
10 μm and 600 per container for particles larger than 25 μm.
For larger volumes (more than 100 mL), HIAC particle
pass/fail limits are 12 per mL for particles above 10 μm and 2
particles per mL for particles above 25 μm. Performing an in-
use stability study allows the development team to under-
stand any risks around interfacial interaction of the protein
with the clinical components, as well as to define a safe
operating space for clinical studies.
Subcutaneous delivery of therapeutic proteins is a fast-
growing field, which often requires large quantities of drug to
be administered within a small volume. High protein concen-
tration drug products are conventionally delivered with
different types of syringes and needles. Recently, prefilled
syringes, autoinjectors, or on-body delivery systems have
been increasingly utilized in subcutaneous drug delivery. In-
use stability studies should include the evaluation of interfa-
cial impact from the surfaces of those injection devices and
the approaches to use them during administration.
ANALYTICAL METHODS TO ASSESS INTERFACE-
MEDIATED PROTEIN AGGREGATION
Biologics subjected to interfacial stress can generate a
diverse assortment of aggregated species ranging in size from
dimers and other soluble aggregates, to subvisible or
micrometer-sized particles, to particles in the hundreds of
micrometers that are visible to the unaided eye. Due to this
size diversity, no single analytical technique is capable of
providing a comprehensive assessment of the variety of
aggregates that can be generated by interfacial stress. The
subsequent section presents a brief overview of the analytical
tools useful for characterizing aggregated species, including
techniques that assess secondary/tertiary/higher order struc-
ture, size, and morphology. An analytical and characteriza-
tion strategy needs to be developed that utilizes techniques
that provide insight into the composition, morphology,
mechanism of formation, and quantitation (e.g., mass, particle
count) of the aggregated species. It is beyond the scope of this
paper to delve into the intricacies and limitations of each
technology, as such information has been thoroughly
reviewed elsewhere (79–82). Instead, the reader is directed
to these reviews and the various citations contained through-
out to achieve the appropriate level of understanding.
Analysis and Characterization of Soluble Aggregates
The quantitation and analysis of soluble aggregates (par-
ticularly dimers, but also higher molecular weight species up to
tetramers) is an important element in assessing, characterizing,
andmitigating interfacial stress-induced protein alterations. The
analytical workhorse for simple quantitation of soluble aggre-
gate content is size exclusion chromatography (SEC). The use of
a multi-angle light scattering detector during analysis by SEC
(SEC-MALS) can provide further information regarding the
absolute molecular weight of the aggregate species. For
situations where interprotein disulfide bonds may form due to
the interfacial stress, capillary electrophoresis-sodium dodecyl
sulfate (CE-SDS) can provide valuable insight, due to its
convenient ability to be used in both reduced and nonreduced
formats.
The classic spectroscopic techniques, including ultravio-
let absorbance, circular dichroism (CD), infrared (FTIR),
Raman, and fluorescence (intrinsic and extrinsic), are capable
of measuring changes in secondary and/or tertiary structure
of the monomeric or aggregated forms and may provide
information that can yield a mechanistic understanding of the
root cause of aggregation/particle formation. In hyphenated
microscopy format, FTIR and Raman have found particular
use in characterizing the nature of proteinaceous particles.
Light scattering techniques, such as static light scattering
(SLS) and dynamic light scattering (DLS), can be useful for
characterizing aggregates in the submicron range. The
former, when used in combination with size exclusion
chromatography (e.g., SEC-MALS), is particularly conve-
nient for the characterization of the absolute molecular
weight of soluble aggregates. DLS can provide an assessment
of the hydrodynamic radii and size distribution (although
resolution is limited) of particles and is generally well suited
to detecting small amounts of relatively large aggregates.
Turbidimetry, which measures the reduction in light passing
through a sample, and nephelometry, which measures the
amount of forward scattered light produced by a sample, can
both provide a coarse assessment of particle concentration.
Differential scanning calorimetry may afford an understand-
ing of the stability of the potentially altered conformational
state of the perturbed native state or aggregated states. More
specialized techniques, such as analytical ultracentrifugation
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(AUC), asymmetric flow field-flow fraction (AF4), and
hydrogen deuterium exchange monitored by mass spectrom-
etry (HDX-MS) or FTIR (HDX-FTIR), may also be used to
characterize soluble aggregates formed due to interfacial
stress.
A convenient way to summarize the various measure-
ment approaches describe above is by categorizing them
according to what aspect of the aggregation process they are
measuring (83):
1. Changes in protein secondary and tertiary structure
a. Circular dichroism spectroscopy (CD)
b. Fourier transform infrared spectroscopy (FTIR)
c. Raman spectroscopy
d. Fluorescence spectroscopy
i. Intrinsic
ii. Hydrophobic extrinsic dye binding (Thioflavin
T (Th T), Sypro Orange, 8-anilinonaphthalene-1-
sulfonic acid (ANS), 4,4′-dianilino-1,1′binaphthyl-
5,5′-disulfonic acid (bis-ANS))
e. UV absorbance spectroscopy
f. Differential scanning calorimetry (DSC)
g. Hydrogen–deuterium exchange monitored by
mass spectrometry or FTIR (HDX-MS or HDX-
FTIR)
2. Changes in the number of aggregates and particles
and in the amount of monomeric protein
a. High/ultra performance liquid chromatography
b. Capillary electrophoresis-sodium dodecyl sulfate
(CE-SDS)
c. Static light scattering (SLS)
d. Multi-angle light scattering (MALS)
e. Dynamic light scattering (DLS)
f. Analytical ultracentrifugation (AUC)
g. Asymmetrical flow field-flow fractionation (AF4)
Analysis of Submicron and Subvisible Particles
Submicron particles are generally defined as those
particles between 100 and 1000 nm in size. This size range
will likely gain more attention as the U.S. Food and Drug
Administration Guidance for Immunogenicity Assessment for
Therapeutic Protein Products states that sponsors should
strive to characterize particles in this smaller size range (84).
At present, there are two primary techniques for character-
izing particles in this size range: nanoparticle tracking analysis
(NTA) and resonant mass measurement (RMM). NTA
counts and sizes particles by tracking the Brownian motion
of individual particles within the sample of interest. Tian et al.
have recently contributed an evaluation of NTA and its
application in characterizing submicron, proteinaceous parti-
cles (85). The RMM method (also referred to as SRM, or
suspended microchannel resonator) relies on the measure-
ment of a particle’s buoyant mass to calculate a variety of
useful parameters, including particle size and concentration.
Like flow imaging (described later), this method can be
particularly useful in differentiating silicone oil droplets from
proteinaceous aggregates due to natural differences in
buoyancy (86). An industry effort to use these two methods
to survey the amount of submicron particles in marketed
product is underway and the results should be available soon.
Subvisible particles (SbVP) are typically classified as
those particles in the range of 1 and 100 μm. Particles in this
range must be assessed as part of batch release and are also
an important part of comparability testing and process
development. The batch release methods, light obscuration
(LO) or membrane microscopy analysis, for these particles/
protein aggregates are described in several pharmacopeia
chapters (33,87–89). The LO method is an optical method in
which the amount of light passing through the aliquot being
tested is measured. Whenever a shadow passes over the
detector due to obscuration of the light, this is assumed to be
a particle; the size is determined from the 2D shadow, and
each individual shadow counted. For the membrane micros-
copy method, the sample is filtered, and then the particle size
and number are determined by manual analysis of the filter
(33,87–89).
Characterization of Particle Morphology
As the inherent heterogeneity of proteinaceous particles
became better understood, it became apparent that the
compendial methods were not sufficient for characterization
and root cause analysis (59,60). As a result, new method
development was needed to provide a more detailed descrip-
tion of the particles formed during process development and
characterization. The particles should be assessed for size,
number, morphology, chemical modifications, and conforma-
tion, if they are proteinaceous (90,91). Many review articles
describe the different techniques available for characteriza-
tion (80,81,92), with the compendial chapter <1787> (33)
providing an overview of the methods and their strengths and
weaknesses. Many of these are used for analysis of monomers
and particles across all sizes, including the biophysical
methods described previously.
Particle morphology can be detected using flow imaging
(FI). In this technique, optical images are captured as the
sample flows through the detector and are subsequently
analyzed. In addition to size and number, the images can be
analyzed for brightness, shape, and Feret diameter. This
method can help differentiate protein particles from fibers,
solid spheres, or silicone oil droplets. FI is useful for root
cause analysis; however, the method is not as robust as LO,
and at present, there is no linkage of FI particle counts to
historical specifications using LO as the test methodology.
Thus, while flow imaging is a powerful characterization
technique, it is not currently a batch release method with
the robustness necessary for routine application in a GMP or
quality facility. Both LO and FI are optical methods and,
thus, depend on differences in refractive index between
particle and surrounding solution. The National Institute of
Standards and Technology (NIST) has done extensive studies
comparing these methods to understand why the size
distributions obtained from the same sample are different,
and a thorough discussion of the confounding issues has been
published (93).
USP Chapter <1> requires parenteral dosage forms to be
essentially free from visible particulate matter (94). While the
precise phrase Bessentially free^ may not appear in the
analogous chapters of other global pharmacopeia, the under-
lying intent of such chapters is the same. Visible particles are
most readily assessed by adhering to the basic approach
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outlined in the three International Council for Harmonization
(ICH) region’s pharmacopeia (89,95,96). Briefly, the pharma-
copeia require inspection against black and white back-
grounds using a light intensity of 2000–3750 lx from a white
light source. Even in these controlled lighting conditions, the
detection of visible particles is probabilistic and depends on
many attributes, including both observer- and particle-specific
characteristics. As such, the probability of detecting a single
spherical particle only begins to approach 100% for particles
that are ~ 200 μm and larger, while trained operators may be
able to detect particles in the 50–100-μm range (97). If more
enhanced visible particle detection capabilities are desired,
one can consider the use of manual, table-top inspection
machines such as those from Seidenader (V90-T or VPE) or
Bosch Packaging Technology (APK series or ETAC
ProView). In some instances, these machines can be config-
ured with high-resolution cameras to aid in detection of
visible particles.
Tools for the Evaluation of Interfacial Rheology
The response that an interfacial film of protein and/or
surfactant exhibits when a force is applied to the film provides
a wealth of information about the nature of the molecules
adsorbed to the interface. Interfacial rheology, which mea-
sures this relationship, is therefore a valuable tool to
understand protein aggregation at interfaces. Fuller et al.
wrote a detailed review about the rheology of complex fluid–
fluid interfaces (98). A brief overview of some of the available
techniques for measuring the interfacial rheology of protein/
surfactant films is presented here.
Interfacial rheology is typically performed either as a shear
measurement under constant surface area or as a dilatational
measurement where the surface area is uniformly compressed
or expanded. Interfacial shear measurements performed with
traditional rotational rheometers, which are typically employed
for bulk rheological measurements, are themost common due to
the availability of the instruments. A bicone disk geometry
allows for the measurement of interfacial viscoelasticity of
protein films (99) but can suffer from lack of sensitivity due to
bulk drag on the geometry. The double-wall ring geometry
improves on sensitivity by reducing bulk drag and has also been
successfully employed for the measurement of protein films
(100). However, since the viscoelasticity of interfacial films can
be very low, traditional rotational rheometers do not always
offer sufficient sensitivity.
Academic labs have developed a variety of dedicated
interfacial rheological methods, and some of these are now
commercially available. An interfacial shear rheometer based
on a thin magnetic rod floated at the fluid–fluid interface
(101) provides good sensitivity for the measurement of
interfacial protein films (102) and is commercially available.
To further increase the sensitivity of interfacial shear
measurements, several active microrheology measurements
that use smaller probes can be employed, thus increasing
sensitivity to the interfacial film rather than the bulk fluid(s).
A microrheometer based on the rotation of magnetic 300 nm
rods successfully measured the interfacial viscoelasticity of a
protein film over four orders of magnitude as the film aged at
the air–liquid interface (103). Another microrheometer based
on the rotation of magnetic disks has been used to
characterize the viscoelastic properties of lipid films, but
could be readily adapted to measure interfacial protein films
(104).
While interfacial shear rheometers are ubiquitous, dila-
tational measurements obtained after the surface area is
uniformly compressed and/or expanded offer additional
insight into the properties of protein films. Notably, the
uniform compression of protein films adsorbed to an air–
liquid interface highlighted the difference in aggregation
propensities of two mAbs (105), as well as showed that
particle shedding from the interface depended on the extent
of compression and the length of exposure of the antibody to
the air–liquid interface (13).
Tools for the Quantification of Adsorption Dynamics
As discussed throughout this paper, the adsorption of
therapeutic proteins to interfaces can drive the lateral
aggregation of those confined proteins. Therefore, measuring
both the adsorption dynamics of proteins and the interfacial
phase behavior can play an important role in biotherapeutic
development. In parallel, the role of surfactants in multicom-
ponent systems with proteins can be quantified, as the
competitive adsorption process is known to limit protein
adsorption.
One of the oldest and most ubiquitous methods for
measuring adsorption to fluid–fluid interfaces is surface
(interfacial) tension. Surface tension was used to predict the
aggregation propensity of a panel of mAbs and, therefore, could
serve as a method for identifying problematic protein molecules
early during development (10). Two common techniques are
available commercially for the measurement of quasi-static
surface tension on timescales of seconds to hours: the Wilhelmy
plate method and the pendant drop method. TheWilhelmy plate
method directly measures the force acting on a flag placed at the
fluid–fluid interface. This method typically requires milliliters of
solution to measure. The pendant drop (or pendant bubble)
apparatus works by allowing a ~ 1-mm-diameter drop of fluid to
equilibrate in another bulk fluid, allowing for protein and
surfactant to adsorb to the interface. The pendant shape of the
drop is a balance between the tension of the interface and gravity
acting on the drop, as described by the Young–Laplace equation.
The pendant drop technique has been used to examine the
kinetics of protein adsorption to fluid–fluid interfaces (106–108).
This method typically requires ~ 5 mL of solution to measure the
dynamics of surface tension; however, there have been recent
developments to build a microfluidic-based pendant bubble/drop
apparatus that requires ~ 20 μL of solution (109,110).
As proteins begin to populate the interface from the
aqueous buffer, the surface concentration increases and
lateral interactions between proteins will define a 2D phase
behavior that can be visualized using microscopy tools such as
Brewster angle microscopy (BAM) or fluorescence-based
microscopy. The execution of a BAM experiment mirrors
the Wilhelmy plate setup described above, where proteins
adsorb to the air–water interface as a function of time. BAM
images in situ changes in refractive index at the air–water
interface. At 53°, the Brewster angle of an air–water
interface, minute changes in refractive index at the interface
can be imaged, visualizing aggregation as well as multilayer
formation (111,112).
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Fluorescence-based microscopy techniques can also
quantify adsorption and examine protein aggregation at
various interfaces. These techniques typically require an
extrinsic fluorophore to label the protein or molecule of
interest, but carefully choosing the dye and limiting the
labeling can allow for excellent visualization while not
compromising the interfacial behavior of the molecule.
Confocal microscopy, which provides good axial resolution
for selectively observing interfacial phenomena, can be used
to quantify the amount of protein adsorbed to an interface
either in a Langmuir trough (113) or in a microtrough
requiring less than 100 μL of solution (10). Total internal
reflection fluorescence (TIRF) microscopy utilizes an evanes-
cent wave to selectively visualize molecules within a few
hundred nanometers from a solid–liquid or liquid–liquid
interface. TIRF has been used to track single protein
molecules at an oil–water interface to determine adsorption
and aggregation kinetics (114).
The change in surface tension upon changing the surface
area available to an adsorbed film of protein and surfactant
also provides useful information about adsorption dynamics.
A Langmuir trough provides a controlled compression/
expansion rate and allows for the simultaneous measurement
of surface tension and other properties (6,14). The decrease
in surface tension upon compression suggested strong
protein–protein interactions in adsorbed films of antibodies
(6,14), and the hysteresis experienced upon compression and
then expansion may indicate loss of material from the
interface into the bulk and/or an irreversible change in the
protein film due to compression. Protein films formed at the
air–liquid interface can then also be transferred to a flat, solid
substrate for subsequent topological characterization with
atomic force microscopy, a combination that was used to
better understand particle formation of an antibody at the
air–liquid interface (14).
A multitude of label-free methods can be used to
measure the adsorption of proteins and surfactants to solid–
liquid and liquid–liquid interface. Quartz crystal microbalance
with dissipation monitoring (QCM-D) measures the change
in resonant frequency of a quartz crystal as different materials
adsorb to the surface. The crystal may be functionalized with
various materials like silicone oil, polymers, and metals.
QCM-D measures the wet mass, which includes the molecules
of interest as well as any hydration layer around those
molecules, and has been used to study therapeutic protein
adsorption to silicone oil–water interfaces (115). While QCM-
D can provide sensitive equilibrium adsorption measurements
and can also measure the viscoelasticity of the adsorbed films,
it is not well suited for measuring adsorption kinetics.
However, several other label-free techniques provide highly
sensitive adsorption kinetics at solid–liquid and liquid–liquid
interfaces. Well-established tools to examine the rate of
adsorption and the developing thickness of the protein-
based film include ellipsometry (116,117) and surface en-
hanced Raman spectroscopy (118,119). Recently developed
tools include optical waveguide lightmode spectroscopy
(OWLS), surface plasmon resonance (SPR), biolayer inter-
ferometry (BLI), and sum frequency generation (SFG).
OWLS and SPR work on a similar principle of producing
an evanescent wave to measure the local change in refractive
index within approximately 100 nm of the surface due to
adsorption of molecules. Both have been used to understand
the interplay between surfactants and proteins adsorbing to
solid–liquid interfaces (120,121). However, due to the sensi-
tivity to refractive index changes, OWLS and SPR can both
suffer from matrix effects. In contrast, BLI measures a
wavelength shift due to the thickness and optical properties
of an adsorbed layer to a solid substrate, so it can therefore
be used in complex sample matrices. The substrate can be
modified, as with the other techniques mentioned above, and
this tool has been used to measure protein adsorption and
desorption kinetics to various polymer-modified surfaces
(122). SFG uses two incident beams, one in the visible and
one in the IR to create a Bsum frequency.^ The IR beam is
broadly tuned to match the vibrational transition of the C–H
or amide I group. SFG can only probe systems where
inversion symmetry is broken, which occurs at the interface
and not in the bulk. Because of the interfacial sensitivity, SFG
can be used to simultaneously quantify adsorption rates,
secondary structure, and structural orientation at the inter-
face (123).
Due to the advantages and disadvantages of each of
these methods for measuring protein and surfactant adsorp-
tion dynamics, a combination of techniques is likely necessary
to provide a mechanistic understanding of protein adsorption
and response to stress at the interface.
RECOMMENDATIONS
Biologic molecules encounter multiple types of interfaces
during development, manufacturing, and throughout the
lifetime of the product. Here, we have highlighted many of
the interfacial stress conditions to which proteins are exposed,
as well as the effect of these stresses on the stability of the
drug substance and drug product, and methods used to
characterize. While some mitigation strategies, such as the
addition of surfactant, are relatively common, other risk
assessment tools and strategies around evaluation of interfa-
cial sensitivity of a given protein should be considered. Each
protein has its own unique sensitivities, and in order to
develop a robust drug product, it is important to understand
the different risks for each molecule. While some recommen-
dations have been made within each section, here we provide
a summary of recommendations during different stages of
biologics product development.
Drug Substance
When working with an inherently sensitive molecule,
development and manufacturing of a drug substance may be
of particular concern, as during the drug substance
manufacturing process for many molecules, no surfactant is
present until the final step. Until the risk of exposure to
interfacial stress has been evaluated, a conservative operating
space should be employed and exposure to excessive
interfacial stress should be avoided. Experience is gained as
each molecule moves through the development process, but
risk assessment tools should be applied to better understand
the effect of interfacial stress on a given protein. In particular,
agitation studies and freeze/thaw studies are often performed
early in the development process. In these studies, the
product is exposed to agitation stress or to multiple freezing
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and thawing cycles, respectively, then characterized via size
exclusion chromatography and particulate analysis, as well as
any specific stability indicating assays important for the
molecule of interest. For example, an agitation study may
include agitation of the molecule on an orbital shaker at
moderate rate for 1 to 7 days, or a shorter period of agitation
via a wrist action shaker. During the early development
process, an average of five freezing and thawing cycles is
often performed, where the molecule is cycled between −
70°C and room temperature, and then analyzed for HMWS
and particle formation after each cycle to look for any upward
trends. While each company has their own operating space
and product specifications, any significant increase in either
soluble aggregates or particle counts with exposure to
interfacial stress should be examined further and potential
root causes should be evaluated. These early screening tools
can provide insight into the stability of the product under
stress conditions and can allow the development team a
design space in which to operate while designing the
manufacturing process.
Drug Product
Each drug product should also be evaluated for sensitivity
to different interfaces during manufacturing, storage, and
transportation. During drug product manufacturing, the protein
is exposed to freezing/thawing; shear stress and stress at the air/
water interface during stirring, pumping, and filling operations;
and solid/liquid interfacial stress during filtration and with
exposure to different manufacturing components. During
transportation and storage, both container compatibility and
ruggedness with respect to agitation are critical for the long-term
stability of a molecule. Thus, sensitivity to freezing and thawing,
shear and air/water interfacial stress, and solid/liquid interfacial
stresses should all be examined. Because degradation of
surfactant on stability can occur, studies on aged drug product
and/or studies using surfactant levels representative of the end
of shelf life should be performed.
First, in addition to the freezing and thawing studies that
are often performed on small volumes early in development,
scale down models are often used to evaluate performance
with freezing and thawing in smaller containers representa-
tive of the surface area to volume ratio of the target storage
container for commercial drug substance manufacture. In
addition to the agitation studies performed above, after a
drug product presentation is locked, more specific agitation
studies should be performed to ensure the product is robust
enough to handle the interfacial stress sustained during
transportation. Performing these studies at the target fill
volume provides representative conditions for both the air/
water interface and the container compatibility. In particular,
shock testing and shipping tests are often performed on
representative drug product vials prior to commercialization.
In these shipping studies, the drug product is shipped and
exposed to real-world conditions that may arise during
transportation. In particular, using aged drug product for
these studies can account for any surfactant degradation that
may occur over time in certain products, demonstrating the
robustness of the formulation to protect against
transportation-induced interfacial stress, even at the end of
the use period.
Container and manufacturing component compatibility is
also critical. While the majority of commonly used containers
and manufacturing components can be considered low risk
for causing substantial stability challenges, it is still important
to perform a risk assessment and/or a study to ensure no
surprises emerge on stability. For example, small volumes of
bulk drug product can be incubated in the container(s) of
choice for 1 to 3 months under recommended storage
conditions and under appropriate accelerated conditions for
the protein of interest. Similarly, small pieces of each
component of a given manufacturing scheme can be incu-
bated with the bulk drug product for 3 to 7 days at the
temperature anticipated for manufacturing, then compared to
protein simply held at the same temperature in an adjacent
vial. Filtration is likely the unit operation where a solid/liquid
interface problem will emerge; most importantly, protein and
surfactant concentration should be measured before and after
filtration to ensure no material has been lost to the filter. If
material is lost in the first volume to pass through the filter
(for example, in the first 100 mL of a clinical manufacturing
scale filter), but a saturation point is reached, a surge vessel
can be used. Alternatively, a filter flush volume can be built
into the manufacturing instructions in order to saturate the
filter and allow the remainder of the material to pass through
without loss of protein concentration. Different filter types
can also be explored, as some may be more likely to cause
protein adherence than others.
In addition to agitation and interfacial screening tools,
shear rates for different mixing and filling parameters can be
modeled, and mini-piloting tools can be utilized to expose the
molecule to these levels of shear. Interestingly, in some cases,
problems do not manifest in immediate aggregation, but
aggregates may form over time in solutions that have been
exposed to stress. Thus, it is also recommended to expose the
molecule to the anticipated stress condition and then set it on
stability in order to observe any lasting effects the exposure to
interfacial stress may cause. Aggregates and particle counts
should be measured before stress, immediately after stress,
and again after storage at recommended and accelerated
storage conditions.
The described risk assessment tools can also be used to
set an appropriate level of surfactant to be included in a given
formulation. For example, formulations with different levels
of surfactant can be exposed to the same stress conditions,
then evaluated for formation of particles and soluble aggre-
gates. Surfactant degradation should also be considered; in
some cases, surfactants can degrade from either oxidation or
enzymatic activity. Degradation kinetics should be well-
understood to enable prediction of the remaining surfactant
levels at the end of shelf life. Subsequently, enough surfactant
should be added to the formulation to ensure that enough
intact surfactant remains at the end of the use period, so that
even drug shipped to a site and administered to a patient in
the last month of the use period will be stable and safe for
clinical use.
In-Use Stability
Once the drug product has been manufactured and has
reached the clinical site, the steps used in product adminis-
tration can still expose the molecule to stress conditions. A
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thorough description of in-use stability studies can be found
in the BIN-USE STABILITY STUDY OF INJECTABLE
BIOLOGICAL DRUG PRODUCTS^ section above. For IV
infusion, it is important to assess the stability of the product in
the diluents recommended for the product’s administration.
Because dilution of the drug product with the vehicle
inherently dilutes the surfactant, as well, particulate forma-
tion can reemerge as a problem for sensitive molecules. In-
use stability studies are therefore a critical part of the
development process. These studies evaluate the stability of
the molecule when exposed to different diluents and compo-
nents used during product administration, including IV bags,
IV sets, and in-line filters. If the product is to be administered
subcutaneously, the stability of the product in the presence of
the silicone oil and in contact with the administration device
should be considered. Advances in patient drug delivery and
increased interest in patient convenience have led to an
increase in the use of autoinjectors and other self-
administration devices. If these devices are to be used, the
contact surfaces and solid/liquid interfaces encountered
during use should be evaluated for their impact on the
stability of the protein itself. In all cases, the infusion product
should be tested for formation of high molecular weight
species and particulate matter, as well as tested via any
specific stability-indicating assay for the molecule of interest.
CONCLUSIONS
Exposure of proteins to interfaces during development,
manufacturing, and storage is inevitable. Each protein has its
own unique sensitivities, and in order to develop a robust
drug product, it is important to understand the different risks
for each molecule. While some mitigation strategies, such as
the addition of surfactant, are relatively common, other risk
assessment tools and strategies around the evaluation of
interfacial sensitivity of a given protein should be considered.
In this commentary, we have described the interfacial
conditions to which proteins are exposed, the effects interfa-
cial exposure have on the stability of the protein, potential
stability studies and risk assessment tools to understand the
impact on each individual molecule, as well as new analytical
techniques that are available to explore the behavior of
different molecules at the air/liquid and solid/liquid interface.
Understanding the particular sensitivities of a molecule
throughout the development process is key to development
of a robust drug product.
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